Long-Term Safety and Disease Control of Ruxolitinib Cream Among Adolescents With Atopic Dermatitis: Results From Two Phase 3 Studies

Main Article Content

Lawrence Eichenfeld
Eric Simpson
Kim Papp
Jacek Szepietowski
Leon Kircik
Darryl Toth
Seth Forman
Michael Kuligowski
May Venturanza
Haobo Ren
Amy Paller


atopic dermatitis




1. Langan SM, et al. Lancet. 2020;396(10247):345-360.

2. Silverberg NB, Durán-McKinster C. Dermatol Clin.

3. Bao L, et al. JAKSTAT. 2013;2(3):e24137.

4. Oetjen LK, et al. Cell. 2017;171(1):217-228.

5. Papp K, et al. J Am Acad Dermatol. 2021;85(4):863-872.

6. Papp K, et al. Long-term safety and disease control with ruxolitinib cream in atopic dermatitis: results from two phase 3 studies. Presented at: Revolutionizing Atopic Dermatitis Conference, June 13, 2021

Most read articles by the same author(s)

<< < 12 13 14 15 16 17